Docexan
Generic Name
Docetaxel 80 mg Injection
Manufacturer
Generic Pharma Inc.
Country
Global
Loading images...
Price Details
Current market pricing information
| Variant | Unit Price | Strip Price |
|---|---|---|
| docexan 80 mg injection | ৳ 13,900.00 | N/A |
Description
Overview of the medicine
Docetaxel is a potent chemotherapy drug belonging to the taxane class, used to treat various types of cancer. It works by disrupting the internal scaffolding of cancer cells, leading to their death.
Uses & Indications
Dosage
Adults
Typical dose is 75-100 mg/m² administered as a 1-hour intravenous infusion every 3 weeks. Specific dosing depends on the indication and individual patient factors.
Elderly
Generally, no specific dose adjustment is required, but monitor closely for toxicity, especially myelosuppression and fluid retention.
Renal_impairment
No specific dose reduction recommended for mild to moderate renal impairment. Exercise caution and monitor for toxicity in severe renal impairment (CrCl < 30 mL/min).
How to Take
Administer as a 1-hour intravenous infusion. Premedication with oral corticosteroids (e.g., dexamethasone) is typically required starting one day prior to infusion to reduce the incidence and severity of hypersensitivity reactions and fluid retention.
Mechanism of Action
Docetaxel promotes the assembly of microtubules from tubulin dimers and inhibits their depolymerization, resulting in extreme stabilization of microtubules. This leads to the inhibition of cell mitosis and cell division, ultimately causing cancer cell death.
Pharmacokinetics
Onset
Rapid distribution into tissues following intravenous administration.
Excretion
Approximately 80% of the dose is excreted in the feces (as metabolites and unchanged drug), and 6% in the urine within 7 days.
Half life
The elimination profile is triphasic, with a terminal half-life of approximately 4 to 18 hours.
Absorption
Administered intravenously, resulting in 100% bioavailability. Peak plasma concentrations are achieved at the end of the infusion.
Metabolism
Extensively metabolized in the liver, primarily by the cytochrome P450 3A4 (CYP3A4) isoenzyme, into inactive metabolites.
Side Effects
Contraindications
- Severe hypersensitivity to docetaxel or polysorbate 80
- Baseline neutrophil count < 1500 cells/mm³
- Severe liver impairment (bilirubin > ULN, AST/ALT > 1.5 x ULN, alkaline phosphatase > 2.5 x ULN)
- Pregnancy and breastfeeding
Drug Interactions
Live Vaccines
Avoid live vaccines during docetaxel treatment due to increased risk of infection.
CYP3A4 Inhibitors (e.g., Ketoconazole, Erythromycin, Ritonavir)
Concomitant use may increase docetaxel plasma concentrations, leading to increased toxicity. Avoid or use with caution with dose reduction.
CYP3A4 Inducers (e.g., Phenytoin, Carbamazepine, Rifampin, Phenobarbital)
May decrease docetaxel plasma concentrations, potentially reducing efficacy. Avoid concomitant use if possible.
Storage
Store unopened vials at room temperature (20-25°C) and protect from light. Do not refrigerate. After dilution, store at room temperature or refrigerated (2-8°C) for a limited time as specified by the manufacturer.
Overdose
Symptoms of overdose include bone marrow suppression, peripheral neurotoxicity, and mucositis. Management is primarily supportive, including granulocyte-colony stimulating factor (G-CSF) administration for myelosuppression and symptomatic treatment for other toxicities.
Pregnancy & Lactation
Pregnancy Category D. Docetaxel can cause fetal harm when administered to a pregnant woman. Women of childbearing potential should use effective contraception during treatment. It is unknown whether docetaxel is excreted in human milk, but due to potential serious adverse reactions in nursing infants, breastfeeding should be discontinued during treatment.
Side Effects
Contraindications
- Severe hypersensitivity to docetaxel or polysorbate 80
- Baseline neutrophil count < 1500 cells/mm³
- Severe liver impairment (bilirubin > ULN, AST/ALT > 1.5 x ULN, alkaline phosphatase > 2.5 x ULN)
- Pregnancy and breastfeeding
Drug Interactions
Live Vaccines
Avoid live vaccines during docetaxel treatment due to increased risk of infection.
CYP3A4 Inhibitors (e.g., Ketoconazole, Erythromycin, Ritonavir)
Concomitant use may increase docetaxel plasma concentrations, leading to increased toxicity. Avoid or use with caution with dose reduction.
CYP3A4 Inducers (e.g., Phenytoin, Carbamazepine, Rifampin, Phenobarbital)
May decrease docetaxel plasma concentrations, potentially reducing efficacy. Avoid concomitant use if possible.
Storage
Store unopened vials at room temperature (20-25°C) and protect from light. Do not refrigerate. After dilution, store at room temperature or refrigerated (2-8°C) for a limited time as specified by the manufacturer.
Overdose
Symptoms of overdose include bone marrow suppression, peripheral neurotoxicity, and mucositis. Management is primarily supportive, including granulocyte-colony stimulating factor (G-CSF) administration for myelosuppression and symptomatic treatment for other toxicities.
Pregnancy & Lactation
Pregnancy Category D. Docetaxel can cause fetal harm when administered to a pregnant woman. Women of childbearing potential should use effective contraception during treatment. It is unknown whether docetaxel is excreted in human milk, but due to potential serious adverse reactions in nursing infants, breastfeeding should be discontinued during treatment.
Frequently Asked Questions
Common questions about this medicine
Pack Sizes
Shelf Life
Typically 24 to 36 months when stored as recommended. Refer to the specific product's labeling for exact shelf life.
Availability
Available in hospitals, oncology clinics, and specialized pharmacies.
Approval Status
Approved by major regulatory bodies (e.g., FDA, EMA, DGDA)
Patent Status
Off-patent (generic available)
WHO Essential Medicine
YesClinical Trials
Extensive clinical trials have established the efficacy and safety of docetaxel across multiple cancer types. Ongoing research continues to explore its use in new indications, combination therapies, and novel formulations.
Lab Monitoring
- Complete Blood Count (CBC) with differential before each cycle and weekly during treatment.
- Liver Function Tests (LFTs) including AST, ALT, bilirubin, and alkaline phosphatase before each cycle.
- Renal function tests (Creatinine, BUN) periodically.
Doctor Notes
- Ensure proper premedication with corticosteroids before each infusion to mitigate hypersensitivity and fluid retention.
- Monitor CBCs frequently, especially neutrophil count, and adjust dose or delay treatment if myelosuppression is severe.
- Assess liver function before each cycle; dose modification may be required in patients with hepatic impairment.
- Educate patients on potential side effects, particularly peripheral neuropathy and signs of infection.
Patient Guidelines
- Report any signs of infection (fever, chills) immediately.
- Be aware of symptoms of peripheral neuropathy (numbness, tingling) and report them to your doctor.
- Stay hydrated and maintain good oral hygiene to minimize mucositis.
- Use effective contraception during and for a period after treatment.
Missed Dose Advice
As this medicine is administered under strict medical supervision, a missed dose is unlikely. If a scheduled dose is missed, contact your healthcare provider immediately for instructions on rescheduling.
Driving Precautions
Docetaxel may cause fatigue, dizziness, or visual disturbances. Patients should be advised to exercise caution when driving or operating machinery if they experience these side effects.
Lifestyle Advice
- Avoid crowded places and sick individuals, especially when blood counts are low.
- Maintain a balanced diet and engage in light exercise if tolerated to manage fatigue.
- Discuss hair loss management strategies with your healthcare team.
Alternative Medicines in Bangladesh
Similar medicines available in the market
Global Brand Names
International brand names for this medicine. Click a brand to search for detailed information.
Other Medicines in Docexan Brand
Other medicines available under the same brand name
